Hepta raises $6.7 million in seed funding led by Felicis Ventures and Illumina Ventures to enhance liquid biopsy technology for liver disease detection.
PRIVATENov 05, 2025
Amount Raised
$6.7 Million
Round Type
Seed
San FranciscoBiotechnologyHealth CareArtificial IntelligenceHealth Diagnosticsresearch
Investors
Alumni VenturesSea X VenturesFelicisSeaX VenturesAme Cloud VenturesIllumina Ventures
Description
Hepta, a biotech company, has emerged from stealth with $6.7 million in seed funding. The funding, led by Felicis Ventures and Illumina Ventures, will help advance their liquid biopsy platforms. Hepta's technology interprets cfDNA to provide insights into chronic diseases, particularly liver disease. The company aims to improve diagnostic accuracy for MASH, a severe liver condition affecting millions.
Company Information
Company
Hepta
Location
San Francisco, California, United States
About
Hepta detects chronic disease early by using cfDNA epigenetic analysis and AI to deliver accurate, non-invasive diagnostics at population scale. Founded by former Illumina, Grail and Google scientists, the company is backed by Felicis Ventures, Illumina Ventures, SeaX Ventures, Alumni Ventures, and AME Cloud Ventures. Hepta is proving that blood-based epigenetic biomarkers can replace invasive biopsies, enabling earlier and more accessible detection of diseases like MASH and laying the foundation for future applications across chronic diseases.
Fundz sees it the moment Hepta raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San FranciscoBiotechnologyHealth CareArtificial IntelligenceHealth Diagnosticsresearch